Share on StockTwits

Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded by research analysts at JMP Securities from a “market perform” rating to an “outperform” rating in a report released on Thursday, TheFlyOnTheWall.com reports. The firm currently has a $24.00 price target on the stock. JMP Securities’ price objective would suggest a potential upside of 52.41% from the stock’s previous close.

INFI has been the subject of a number of other recent research reports. Analysts at Roth Capital reiterated a “positive” rating on shares of Infinity Pharmaceuticals in a research note on Wednesday. Separately, analysts at Wedbush upgraded shares of Infinity Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Wednesday. They now have a $15.00 price target on the stock, up previously from $9.00. Finally, analysts at William Blair upgraded shares of Infinity Pharmaceuticals to an “outperform” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $18.11.

Infinity Pharmaceuticals (NASDAQ:INFI) opened at 15.96 on Thursday. Infinity Pharmaceuticals has a one year low of $8.40 and a one year high of $21.60. The stock has a 50-day moving average of $10.58 and a 200-day moving average of $11.34. The company’s market cap is $775.4 million. Infinity Pharmaceuticals also was the recipient of unusually large options trading activity on Wednesday. Traders bought 10,671 put options on the company. This represents an increase of 1,206% compared to the average volume of 817 put options.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings data on Tuesday, August 5th. The company reported ($0.78) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.84) by $0.06. During the same quarter last year, the company posted ($0.68) earnings per share. Infinity Pharmaceuticals’s revenue was up NaN% compared to the same quarter last year. Analysts expect that Infinity Pharmaceuticals will post $-3.48 EPS for the current fiscal year.

Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.

The Fly On The Wall

Receive News & Ratings for Infinity Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.